A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses
© His Majesty the King in Right of Canada, as represented by the Minister of Health (2023)..
Filoviruses, including ebolaviruses and marburgviruses, can cause severe and often fatal disease in humans. Over the past several years, antibody therapy has emerged as a promising strategy for the treatment of filovirus disease. Here, we describe 2 distinct cross-reactive monoclonal antibodies (mAbs) isolated from mice immunized with recombinant vesicular stomatitis virus-based filovirus vaccines. Both mAbs recognized the glycoproteins of multiple different ebolaviruses and exhibited broad but differential in vitro neutralization activities against these viruses. By themselves, each mAb provided partial to full protection against Ebola virus in mice, and in combination, the mAbs provided 100% protection against Sudan virus challenge in guinea pigs. This study identified novel mAbs that were elicited through immunization and able to provide protection from ebolavirus infection, thus enriching the pool of candidate therapeutics for treating Ebola disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 228(2023), Suppl 7 vom: 13. Nov., Seite S691-S700 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Guodong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.11.2023 Date Revised 25.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad205 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357904516 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357904516 | ||
| 003 | DE-627 | ||
| 005 | 20240425232252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad205 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM357904516 | ||
| 035 | |a (NLM)37288609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Guodong |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.11.2023 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © His Majesty the King in Right of Canada, as represented by the Minister of Health (2023). | ||
| 520 | |a Filoviruses, including ebolaviruses and marburgviruses, can cause severe and often fatal disease in humans. Over the past several years, antibody therapy has emerged as a promising strategy for the treatment of filovirus disease. Here, we describe 2 distinct cross-reactive monoclonal antibodies (mAbs) isolated from mice immunized with recombinant vesicular stomatitis virus-based filovirus vaccines. Both mAbs recognized the glycoproteins of multiple different ebolaviruses and exhibited broad but differential in vitro neutralization activities against these viruses. By themselves, each mAb provided partial to full protection against Ebola virus in mice, and in combination, the mAbs provided 100% protection against Sudan virus challenge in guinea pigs. This study identified novel mAbs that were elicited through immunization and able to provide protection from ebolavirus infection, thus enriching the pool of candidate therapeutics for treating Ebola disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Ebola virus | |
| 650 | 4 | |a Sudan virus | |
| 650 | 4 | |a cross-reactive antibodies | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Combined Antibody Therapeutics |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a He, Shihua |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zirui |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Wenguang |e verfasserin |4 aut | |
| 700 | 1 | |a Rahim, Md Niaz |e verfasserin |4 aut | |
| 700 | 1 | |a Audet, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Garnett, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Wec, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Chandran, Kartik |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Xiangguo |e verfasserin |4 aut | |
| 700 | 1 | |a Banadyga, Logan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 228(2023), Suppl 7 vom: 13. Nov., Seite S691-S700 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:Suppl 7 |g day:13 |g month:11 |g pages:S691-S700 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad205 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e Suppl 7 |b 13 |c 11 |h S691-S700 | ||